Validation pour Ingenuity407

vers la météo de la validation par utilisateur

Ingenuity407

precedent - 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 - suivant

Phrase 85 - PMID ?

Oral administration of NODE ( with a treatment period of 2 weeks ) is involved in expression of SP Phosphofructokinase [Pfk] mRNA(s) in adipocytes from SP that involves mutant SP NODE gene ( unspecified homozygous gene mutation ) in SP .

Non annotée
Je ne sais pas
Je n'ai pas trouvé d'analyse satisfaisante

Commentaires :

Analyse 0

                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                                 
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 1

                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                                 
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 2

                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                                 
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 3

                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                                 
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 4

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 5

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 6

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 7

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 8

                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+                          +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                          |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 9

                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+                          +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                          |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 10

                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+                          +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                          |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 11

                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+                          +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                          |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 12

                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 13

                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 14

                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 15

                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 16

                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                                 
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 17

                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                                 
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 18

                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                                 
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 19

                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                                 
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 20

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+                                                                                                          |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                                                 +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 21

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+                                                                                                          |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                                                 +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 22

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+                                                                                                          |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                                                 +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 23

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+                                                                                                          |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                                                 +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 24

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 25

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 26

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 27

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 28

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 29

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 30

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 31

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 32

                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                                       |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 33

                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                                       |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 34

                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                                       |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 35

                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                                       |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 36

                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 37

                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 38

                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 39

                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 40

                                                                                            +-----------------------COMP:N-N(in)----------------------+                          +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+            |                          |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 41

                                                                                            +-----------------------COMP:N-N(in)----------------------+                          +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+            |                          |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 42

                                                                                            +-----------------------COMP:N-N(in)----------------------+                          +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+            |                          |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 43

                                                                                            +-----------------------COMP:N-N(in)----------------------+                          +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+            |                          |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 44

                                                                                            +-----------------------------COMP:N-N(from)----------------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                          |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 45

                                                                                            +-----------------------------COMP:N-N(from)----------------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                          |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 46

                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+----------------SUBJ:V-N---------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 47

                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+----------------SUBJ:V-N---------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 48

                                                                                            +-----------------------------COMP:N-N(from)----------------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                          |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 49

                                                                                            +-----------------------------COMP:N-N(from)----------------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                          |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 50

                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+----------------SUBJ:V-N---------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 51

                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+----------------SUBJ:V-N---------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 52

                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+----------------SUBJ:V-N---------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 53

                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+----------------SUBJ:V-N---------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 54

                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+----------------SUBJ:V-N---------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 55

                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+----------------SUBJ:V-N---------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 56

                                                                                            +-----------------------------COMP:N-N(from)----------------------------+                                                                                                 
                                                                                            +-----------------------COMP:N-N(in)----------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 57

                                                                                            +-----------------------------COMP:N-N(from)----------------------------+                                                                                                 
                                                                                            +-----------------------COMP:N-N(in)----------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 58

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                                       |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 59

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                                       |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 60

                                                                                            +-----------------------------COMP:N-N(from)----------------------------+                                                                                                 
                                                                                            +-----------------------COMP:N-N(in)----------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 61

                                                                                            +-----------------------------COMP:N-N(from)----------------------------+                                                                                                 
                                                                                            +-----------------------COMP:N-N(in)----------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 62

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                                       |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 63

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                                       |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 64

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 65

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 66

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 67

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 68

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+                                                                                                          |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                                                 +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 69

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+                                                                                                          |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                                                 +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 70

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+                                                                                                          |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                                                 +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 71

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+                                                                                                          |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                                                 +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 72

                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                                 
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 73

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------------COMP:N-N(from)----------------------------+                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 74

                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                                 
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 75

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------------COMP:N-N(from)----------------------------+                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 76

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+----------------SUBJ:V-N---------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 77

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+----------------SUBJ:V-N---------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 78

                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                                 
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 79

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------------COMP:N-N(from)----------------------------+                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 80

                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                                 
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 81

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------------COMP:N-N(from)----------------------------+                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 82

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+----------------SUBJ:V-N---------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 83

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+----------------SUBJ:V-N---------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 84

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+----------------SUBJ:V-N---------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 85

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+----------------SUBJ:V-N---------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 86

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+----------------SUBJ:V-N---------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 87

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+----------------SUBJ:V-N---------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 88

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------------COMP:N-N(from)----------------------------+                                                                                            |    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 89

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------------COMP:N-N(from)----------------------------+                                                                                            |    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 90

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------------COMP:N-N(from)----------------------------+                                                                                            |    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 91

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------------COMP:N-N(from)----------------------------+                                                                                            |    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                                         +COMP:N-N(o+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+                 +MOD_ATT:+      +MOD+            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |                 |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,week)
MOD_ATT:N-ADJ (week,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 92

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 93

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 94

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 95

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 96

                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+                          +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                          |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 97

                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+                          +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                          |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 98

                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+                          +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                          |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 99

                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+                          +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                          |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 100

                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 101

                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 102

                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 103

                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 104

                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                                 
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 105

                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                                 
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 106

                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                                 
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 107

                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                                 
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 108

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+                                                                                                          |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                                                 +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 109

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+                                                                                                          |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                                                 +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 110

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+                                                                                                          |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                                                 +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 111

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------COMP:V_PASS-N(in)--------------------------+                                                                                                          |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                                                 +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,adipocytes)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 112

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 113

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 114

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 115

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 116

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 117

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 118

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 119

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               +---------------------------------COMP:V_PASS-N(from)--------------------------------+                                                                                            |    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(from) (involve,__SP__)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 120

                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                                       |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 121

                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                                       |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 122

                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                                       |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 123

                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                                       |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 124

                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 125

                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 126

                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 127

                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 128

                                                                                            +-----------------------COMP:N-N(in)----------------------+                          +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+            |                          |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 129

                                                                                            +-----------------------COMP:N-N(in)----------------------+                          +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+            |                          |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 130

                                                                                            +-----------------------COMP:N-N(in)----------------------+                          +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+            |                          |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 131

                                                                                            +-----------------------COMP:N-N(in)----------------------+                          +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+            |                          |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 132

                                                                                            +-----------------------------COMP:N-N(from)----------------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                          |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 133

                                                                                            +-----------------------------COMP:N-N(from)----------------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                          |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 134

                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+----------------SUBJ:V-N---------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 135

                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+----------------SUBJ:V-N---------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 136

                                                                                            +-----------------------------COMP:N-N(from)----------------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                          |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 137

                                                                                            +-----------------------------COMP:N-N(from)----------------------------+            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                          |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 138

                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+----------------SUBJ:V-N---------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 139

                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+----------------SUBJ:V-N---------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 140

                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+----------------SUBJ:V-N---------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 141

                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+----------------SUBJ:V-N---------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 142

                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+----------------SUBJ:V-N---------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 143

                                                                                                                                                                                 +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+                                       |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+----------------SUBJ:V-N---------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 144

                                                                                            +-----------------------------COMP:N-N(from)----------------------------+                                                                                                 
                                                                                            +-----------------------COMP:N-N(in)----------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 145

                                                                                            +-----------------------------COMP:N-N(from)----------------------------+                                                                                                 
                                                                                            +-----------------------COMP:N-N(in)----------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 146

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                                       |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 147

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                                       |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 148

                                                                                            +-----------------------------COMP:N-N(from)----------------------------+                                                                                                 
                                                                                            +-----------------------COMP:N-N(in)----------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 149

                                                                                            +-----------------------------COMP:N-N(from)----------------------------+                                                                                                 
                                                                                            +-----------------------COMP:N-N(in)----------------------+             |            +----------------------------------COMP:V-N(in)---------------------------------+    
                                                                                            +----------------COMP:N-N(of)----------------+            |             |            |                      +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
COMP:V-N(in) (involve,__SP__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 150

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                                       |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 151

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                                       |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 152

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 153

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 154

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 155

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 156

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+                                                                                                          |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                                                 +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 157

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+                                                                                                          |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                                                 +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 158

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+                                                                                                          |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                                                 +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 159

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+                                                                                                          |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |                                                 +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |                          +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |                          |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            +COMP:N-N(from+--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 160

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------------COMP:N-N(from)----------------------------+                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 161

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------------COMP:N-N(from)----------------------------+                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 162

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+----------------SUBJ:V-N---------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 163

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+----------------SUBJ:V-N---------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 164

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------------COMP:N-N(from)----------------------------+                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 165

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------------COMP:N-N(from)----------------------------+                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+                          |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                          |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+                          |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 166

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+----------------SUBJ:V-N---------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 167

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+                                       +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+----------------SUBJ:V-N---------------+       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+COMP:N-N(from+            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (adipocytes,__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 168

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+----------------SUBJ:V-N---------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 169

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+----------------SUBJ:V-N---------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 170

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+----------------SUBJ:V-N---------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 171

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +----------------COMP:N-N(of)----------------+                                                              +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+----------------SUBJ:V-N---------------+--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+------COMP:N-N(from)------+            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+COMP:N-N(in)+             |            |       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
COMP:N-N(in) (mRNA(s),adipocytes)
COMP:N-N(from) (mRNA(s),__SP__)
SUBJ:V-N (involve,mRNA(s))
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 172

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------------COMP:N-N(from)----------------------------+                                                                                            |    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 173

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------------COMP:N-N(from)----------------------------+                                                                                            |    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 174

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------------COMP:N-N(from)----------------------------+                                                                                            |    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-ADJ (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)

Analyse 175

                                                                               +--------------------------------------------------------------------------------COMP:V_PASS-N(in)--------------------------------------------------------------------------------+    
                                                                               |            +-----------------------------COMP:N-N(from)----------------------------+                                                                                            |    
                                                                               |            +-----------------------COMP:N-N(in)----------------------+             |                                                                                            |    
                                                                               |            +----------------COMP:N-N(of)----------------+            |             |                                   +-------------------APPOS-------------------+            |    
             +--------------------------SUBJ:V_PASS-N--------------------------+            |           +----------MOD_ATT:N-ADJ---------+            |             |            +--------OBJ:V-N-------+                +-------MOD_ATT:N-ADJ------+            |    
             |                       +-----------OBJ:V-N----------+            |            |           |            +----MOD_ATT:N-N----+            |             |            |       +-MOD_ATT:N-ADJ+                |           +-MOD_ATT:N-ADJ+            |    
   +MOD_ATT:N+-COMP:N-N(of)-+        |        +MOD_ATT:+COMP:N+   |            +COMP:V_PASS-+           |            |            +MOD_AT+            |             +--SUBJ:V-N--+       |      +MOD_ATT+                |           |       +MOD_AT+            |    
   |         |              |        |        |        |      |   |            |            |           |            |            |      |            |             |            |       |      |       |                |           |       |      |            |    
 Oral administration of __NODE__ ( with a treatment period of 2 weeks ) is involved in expression of __SP__ Phosphofructokinase [Pfk] mRNA(s) in adipocytes from __SP__ that involves mutant __SP__ __NODE__ gene ( unspecified homozygous gene mutation ) in __SP__ .
MOD_ATT:N-N (administration,oral)
COMP:N-N(of) (administration,__NODE__)
OBJ:V-N (with,week)
MOD_ATT:N-N (period,treatment)
COMP:N-N(of) (period,2)
SUBJ:V_PASS-N (involve,administration)
COMP:V_PASS-N(in) (involve,expression)
COMP:V_PASS-N(in) (involve,__SP__)
COMP:N-N(of) (expression,mRNA(s))
COMP:N-N(in) (expression,adipocytes)
COMP:N-N(from) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA(s),__SP__)
MOD_ATT:N-N (mRNA(s),Phosphofructokinase)
MOD_ATT:N-N (mRNA(s),[Pfk])
SUBJ:V-N (involve,__SP__)
OBJ:V-N (involve,__NODE__)
MOD_ATT:N-ADJ (__NODE__,mutant)
MOD_ATT:N-ADJ (__NODE__,__SP__)
APPOS (__NODE__,mutation)
MOD_ATT:N-ADJ (mutation,unspecified)
MOD_ATT:N-ADJ (mutation,homozygous)
MOD_ATT:N-N (mutation,gene)